Resmetirom Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is the free-acid, non-salt active substance identified by CAS registry number 920509-32-1, molecular formula C17H12Cl2N6O4, and molecular weight 435.22 g/mol. The chemical structure is 2-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy]phenyl]-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile. Four production models are supplied under the same chemical identity: oral non-micronised, oral micronised, granule-grade, and injectable aseptic-ready. They are distinguished by particle size distribution, bioburden, endotoxin limit, residual water, and packaging configuration rather than by a change in the active moiety.

The API is intended solely for further pharmaceutical manufacture and is not administered directly. In finished oral dosage forms—tablet, capsule, and granule presentations—the active substance supports the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis under the prescribing conditions of the approved finished medicine. The injectable presentation is supplied for clinical or formulation development where parenteral delivery is required; the approved indication for the oral tablet product does not automatically transfer to an injectable product, and route-specific toxicology and pharmacokinetic bridging are required.

What Release and Stability Controls Distinguish Pharma Grade Resmetirom API from Non-GMP Material?

The pharmaceutical grade is differentiated from laboratory reagent carrying the same CAS number by the existence of a CTD Module 3.2.S data package, a drug master file available for regulatory citation, stability batches stored per ICH Q1A(R2), and a release testing programme that covers identity, purity, solvent residues, elemental impurities, and route-specific contaminants. Analytical methods are qualified under ICH Q2(R1); critical methods are stability-indicating under forced degradation conditions relevant to the pyridazinone and triazine-dione moieties.

Stability storage is conducted under long-term 25°C/60% RH, intermediate 30°C/65% RH, and accelerated 40°C/75% RH conditions according to ICH Q1A(R2). The re-test period is assigned from multi-lot data for oral and injectable presentations. Published data for the parenteral formulation configuration remain limited; formulators should generate in-use stability data at the intended pH, diluent composition, and container closure system rather than extrapolating from solid-state stability.

Solid-State Polymorphic Control and Micronisation Boundaries

The API is released as a crystalline powder with XRPD pattern concordance to the qualified reference standard under USP <941>. The solid-state form is monitored because comminution during micronisation can introduce amorphous surface disorder and increase hygroscopicity. Micronised material is produced by air-jet milling or rotary milling under nitrogen sweep; the feed rate, grinding pressure, classifier speed, and inlet dew point are recorded as critical process parameters. Over-micronisation reduces the D50 but can reduce the effective surface area available for dissolution due to agglomeration and static charge; under-micronisation shifts the dissolution-limited absorption profile in a direction that may delay release in pH-dependent media. Surface area is measured by nitrogen adsorption per ISO 9277, and particle size is measured by laser diffraction per ISO 13320:2020. The micronised grade is supplied with a D50 and D90 release range derived from production batches and dissolution profiles; the non-micronised grade is controlled for upper particle size to support blending and content uniformity.

Thermal analysis by differential scanning calorimetry is performed per ISO 11357-1; thermogravimetric analysis is used to detect solvent loss or solvate content. If a desolvated form is detected, the lot is re-released only after XRPD confirms reversion to the approved crystalline form. Operational handling boundaries are route-dependent: the oral powder should be dispensed in humidity-controlled areas below 60% RH where possible. If the container has been opened in humid conditions, drying under vacuum at 40°C may be performed only after moisture mapping and stability evaluation. Excessive drying can induce electrostatic charge and reduce flow; therefore, drying time is limited by batch-specific moisture capacity.

In tablet manufacture, the oral grade is incorporated by direct compression, dry granulation, or wet granulation. For direct compression, bulk and tapped density are evaluated under USP <616>; flow is characterised with a shear cell or Hall flowmeter, and the method is selected after measuring compressibility index and Hausner ratio. The micronised grade is applied when dissolution or content uniformity requires increased specific surface area, but the selected D90 should be transferred to the blending operation only after confirming that cohesive behaviour does not cause segregation in a low-shear tumble blender. Loss-on-drying is checked under USP <731> before dispensing to correct the assay input on an anhydrous basis.

Wet granulation requires binder addition level and spray rate adjusted to avoid overwetting because the free-acid form has limited aqueous solubility and its particle surface may become tacky as the granulation liquid evaporates. Aqueous granulation can be processed at a controlled moisture endpoint, but non-aqueous granulation solvents may be required when the formulation contains water-sensitive disintegrants or when the dry weight loss exceeds the approved limit. Drying is performed in a fluid-bed dryer with inlet air temperature and dew point controlled; residual moisture is measured by Karl Fischer titration. The drying endpoint is critical because a residual water level above the approved limit can accelerate hydrolytic degradation of the pyridazinone ring during long-term storage.

Capsule filling operations use a powder sieved through a 0.5 mm or smaller screen after blending to reduce agglomerates. Fill weight is monitored to better than ±2% relative standard deviation on production-scale dosators. Compatibility with hard-shell capsule materials is tested by storing filled capsules at 25°C/60% RH and 40°C/75% RH for at least 6 months; the generated data belong to the formulation development report, not the API release specification.

Granule presentations are released for use as intermediate blends or for sachet filling. The granule particle size is controlled by sieve analysis under USP <786>, and the amount of fines below 75 μm is held within batch-specific limits to reduce dusting and segregation during packaging. Dry granulation by roller compaction is preferred when the API is heat-sensitive or when the formulation cannot tolerate moisture; compaction pressure, roll gap, and screen size are recorded as critical process parameters because excessive densification can reduce the dissolution of milled granules.

Formulation development batches should include a dissolution method that discriminates particle size and polymorphic change. The oral tablet and capsule dissolution test is typically conducted using USP <711> apparatus 2, paddle, or apparatus 1, basket, in 900 mL of media; because the free-acid form is weakly soluble, a surfactant may be required to maintain sink conditions. The method is qualified for linearity, accuracy, and specificity under ICH Q2(R1), and acceptance criteria are linked to clinical exposure data rather than a generic pharmacopoeial endpoint.

When Sterile Injectable Grade Is Specified, Manufacturing Constraints Shift to Endotoxin and Subvisible Particulate Control

The injectable grade starts from the same controlled chemical synthesis, but the downstream refinement includes additional bioburden reduction, aseptic processing of the bulk powder, and terminal dry-heat treatment only where thermal stability data support it. The free-acid structure may be thermally sensitive; therefore, aseptic crystallisation, filtration, and drying under ISO 14644-1 cleanroom conditions are more common than terminal sterilisation of the final filled container. If terminal sterilisation is attempted, dry heat at 160°C for 2 h or gamma irradiation must be validated against assay, related substances, solid-state form, and moisture, because radiolysis or thermal degradation can generate free radicals in the triazine-dione ring.

For solution dosage forms, the injectable grade is reconstituted or dissolved under conditions selected from solubility screening in buffered media. Published data for this specific formulation configuration are limited; formulators must determine equilibrium solubility at the intended pH, ionic strength, and co-solvent level. If the drug substance is poorly water-soluble, parenteral vehicles containing propylene glycol, polyethylene glycol, or cyclodextrin derivatives may be evaluated, but the final choice must satisfy USP <785> osmolality and USP <788> particulate requirements for parenterals. Precipitation upon dilution with blood or infusion fluids is a process conflict: a formulation that appears clear in the vial may crystallise when the solvent environment changes, so in-use stability studies should include phase-contrast microscopy and dynamic light scattering at clinically relevant dilutions.

Subvisible particulate control for injectable presentations is governed at the finished-product level by USP <788> for light obscuration and microscopic particle count. For small-volume parenterals, the light obscuration limits are not more than 3000 particles per container at ≥10 μm and 300 particles per container at ≥25 μm; the bulk API is controlled with internal limits that are tighter to allow particulate contribution from the final container and excipients. Bacterial endotoxin limit is calculated from the maximum intended dose per kilogram body weight; the usual pharmacopoeial K is 5 EU/kg. For a stated maximum daily dose, the API limit is K/M, and the bulk API specification must be sufficiently below the finished-product limit to account for excipients and process water.

For injectable formulation, sterile filtration through a 0.22 μm polyvinylidene fluoride or polyethersulfone membrane is evaluated only after determining drug binding to the membrane. Adsorptive loss to filter materials can reduce assay and potency; therefore, filter compatibility studies include the maximum filter surface area per volume, contact time, and temperature. If the drug substance is present as a suspension, aseptic filtration of the feed solution before crystallisation must be distinguished from terminal filtration of the final dispersion, since the latter cannot be sterilised through a 0.22 μm membrane if the suspended drug particle diameter exceeds the filter rating.

Sterile-grade handling also requires container closure compatibility. The bulk API is packaged in food-grade high-density polyethylene liners inside aluminium or fibre drums; injectable grade is often double-bagged and sealed in a polyester/aluminium/polyethylene laminate to provide a moisture barrier and permit wipe-down transfer into an aseptic filling suite. All packaging materials are tested for leachables and extractables per USP <1663> and USP <1664> when the injectable formulation is in a solvent mixture that may mobilise organic species from the container. Endotoxin control begins in the final crystallisation and drying steps because water used for final recrystallisation must meet WFI quality with endotoxin below 0.25 EU/mL. The final powder is tested by a compendial Limulus amebocyte lysate method; endotoxin can be unevenly distributed, so the sampling plan includes top, middle, and bottom locations in the bulk container.

Compared with non-GMP research reagent carrying the same 920509-32-1 CAS number, this pharmaceutical-grade product is differentiated by full traceability to the API starting material, validated analytical methods, absence of animal-derived raw materials in the registered route unless declared, and a change control system that requires revalidation when a new impurity appears above the identification threshold. Substitution of research-grade material into a registered formulation is not acceptable because the organic impurity profile, residual solvent profile, and elemental catalyst residues may differ across synthetic routes; even when assay and water content appear similar, non-GMP material may contain process-specific impurities that alter dissolution, stability, or injectability.

The product also differs from salt or cocrystal presentations of the same active moiety because the free-acid form has a defined dissolution, pH-solubility, and solid-state stability profile. If a salt form is requested for solubility enhancement, the change from free acid to salt alters the molecular weight correction, assay expression, thermal history, and potentially the route-specific toxicology data; such a change requires a new stability programme and may trigger bioequivalence bridging. Within the broader thyroid hormone receptor beta agonist class, resmetirom has a distinct pyridazinone–triazine dione scaffold and is not interchangeable with earlier pyridazine-based or thyronamine-based candidates. Its impurity profile, synthetic route, and crystal habit are substance-specific; therefore, a supplier qualification programme for this API cannot rely on a class monograph.

The free-acid form is incompatible with strong alkaline solutions above pH 9 if prolonged exposure occurs; formulators should avoid combinations with amine-based alkalising agents in wet granulation or parenteral media without stability confirmation. The oral powder is non-sterile and is not intended for direct use in open wounds or mucosal tissues. For injectable development, all thermal, irradiation, and filtration steps must be qualified on the exact lot because the physical form can shift during processing and because published data for sterilisation of this specific configuration remain limited.